The following is a summary of the BiomX (PHGE) Q1 2024 Earnings Call Transcript:

Financial Performance:

• BiomX reported a cash balance and short-term deposits of $44.1 million as of March 31, 2024, a significant increase from $30.3 million in the same period of 2023.

• Research and development expenses for Q1 2024 are slightly lower, totalling $4.1 million, as compared to $4.6 million for the same period in 2023.

• The company recorded a notable increase in general and administrative expenses for Q1 2024 amounting to $2.7 million, up from $1.6 million for the same period in 2023.

• The net loss for Q1 2024 was significantly more than last year, at $17.3 million compared to $6.4 million in Q1 2023.

Business Progress:

• After the merger with Adaptive Phage Therapeutics in March 2024, BiomX is progressing with a second Phase II product candidate, BX211, aimed at treating diabetic foot osteomyelitis.

• Their leading clinical stage candidate, BX004, has shown encouraging results for treating chronic infections in cystic fibrosis patients.

• Thanks to current funding, BiomX expects to reach multiple clinical milestones through 2025, including the expected data read-outs for lead candidates, BX211 and BX004.

• The company also plans to submit a Phase 2b study protocol for BX004 to all relevant regulatory authorities and commence the study by the end of 2024.

• BiomX's top line results of the Phase 2b study are expected to be released in the third quarter of 2025.

More details: BiomX IR

Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.